Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 9/20 | 0.54 |
| ▸ | EHMT1 | Q9H9B1 | 8/20 | 0.54 |
| ▸ | BCL6 | P41182 | 2/20 | 0.50 |
| ▸ | IDH2 | P48735 | 1/20 | 0.48 |
| ▸ | GALR1 | P47211 | 5/20 | 0.44 |
| ▸ | GALR2 | O43603 | 4/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4829436 | 0.96 | EHMT2 (0.50) | EHMT2EHMT1BCL6IDH2GALR1 | |
| Hydrochloric Acid SCHEMBL5550552 | 0.96 | EHMT2 (0.49) | EHMT2EHMT1BCL6IDH2GALR1 | |
| Bromide SCHEMBL6016985 | 0.96 | EHMT2 (0.49) | EHMT2EHMT1BCL6IDH2GALR1 | |
| Hydrochloric Acid SCHEMBL5550550 | 0.95 | EHMT2 (0.49) | EHMT2EHMT1BCL6IDH2GALR1 | |
| Hydrochloric Acid SCHEMBL5432850 | 0.94 | EHMT2 (0.48) | EHMT2EHMT1BCL6IDH2GALR1 | |
| SCHEMBL4839206 | 0.94 | BCL6 (0.50) | EHMT2EHMT1BCL6IDH2GALR1 | |
| SCHEMBL4836074 | 0.92 | EHMT2 (0.49) | EHMT2EHMT1BCL6GALR1GALR2 | |
| SCHEMBL4838587 | 0.90 | BCL6 (0.47) | EHMT2EHMT1BCL6IDH2GALR1 | |
| Malonic Acid SCHEMBL4829481 | 0.90 | EHMT2 (0.45) | EHMT2EHMT1BCL6IDH2GALR1 | |
| SCHEMBL4838322 | 0.90 | BCL6 (0.57) | EHMT2EHMT1BCL6IDH2GALR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040077648-A1 | Methods and compositions of novel triazine compounds | DR. REDDY'S LABORATORIES LTD. (IN) | 2004-04-22 | — | — | US | claimed |
| US-20040077648-A1 | Methods and compositions of novel triazine compounds | DR. REDDY'S LABORATORIES LTD. (IN) | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077648-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | EHMT2 2905/4885EHMT1 2811/4885BCL6 2097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.